作者
Jingyi Gong, Zsofia D Drobni, Raza M Alvi, Sean P Murphy, Ryan J Sullivan, Sarah E Hartmann, Hannah K Gilman, Hang Lee, Leyre Zubiri, Vineet K Raghu, Rebecca S Karp-Leaf, Amna Zafar, Daniel A Zlotoff, Matthew J Frigault, Kerry L Reynolds, Tomas G Neilan
发表日期
2021/11/1
期刊
European Journal of Cancer
卷号
158
页码范围
99-110
出版商
Pergamon
简介
Background
Immune checkpoint inhibitors (ICIs) are widely used cancer treatments. There are limited data on the risk for developing venous thromboembolism (VTE) among patients on an ICI.
Methods
This was a retrospective study of 2854 patients who received ICIs at a single academic centre. VTE events, defined as a composite of deep vein thrombosis or pulmonary embolism, were identified by individual chart review and blindly adjudicated using standard imaging criteria. A self-controlled risk-interval design was applied with an ‘at-risk period’ defined as the two-year period after and the ‘control period’, defined as the two-year before treatment. The hazard ratio (HR) was calculated using a fixed-effect proportional hazards model.
Results
Of the 2854 patients, 1640 (57.5%) were men; the mean age was 64 ± 13 years. The risk for VTE was 7.4% at 6 months and 13.8% at 1 year after starting an ICI. The rate of VTE …
学术搜索中的文章
J Gong, ZD Drobni, RM Alvi, SP Murphy, RJ Sullivan… - European Journal of Cancer, 2021